Abstract 14501: Empagliflozin Improves 24-Hour Blood Pressure Profiles in Patients With Type 2 Diabetes and Hypertension
2013
A Phase III randomized placebo (PBO)-controlled trial investigated the efficacy and safety of the SGLT2 inhibitor empagliflozin (EMPA) in patients with type 2 diabetes (T2DM) and hypertension. Pati...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI